Malamov E, Kiriakov A, Tsenov I, Kavrukova Iu, Kusitasev G
Vutr Boles. 1982;21(2):91-8.
The serum lipoprotein profile was determined in 37 patients with chronic ischemic heart disease (IHD) and 100 practically healthy subjects, aged from 18 to 45. HLP was found in 59.5 per cent of the patients examined, 50 per cent in males and 100 per cent in females. Type IV has the highest incidence (54.5%), followed by type IIB(36.4%) and type IIa (9.1 per cent). In 27 per cent of the patients with no HLP determined, less significant changes in LDLP and VLDLP were found, admitted to be dyslipoproteinemia (DLP). HLP and DLP were confirmed in 86.5 per cent of the patients examined. In all patients serum concentration of HDLP-Chol was decreased (mostly in DLP and type IV HLP), whereas the level of HDLP-Tg was increased in most of the cases. As a result, the intralipoprotein index 1(2)(=HDLP-Chol/HDLP-Tg) was decreased, reaching the lowest values in IIa and type IV HLP. The only index of all studied, being changed (elevated) with a statistical significance in all groups of patients with IHD, in those with normolipoproteinemia (NLP) including, was the lipoprotein index II(=LDLP-Chol and VLDLP-Chol/HDLP-Chol). With the morbid process progressing, assessed by ECG data, the functional stage of stenocardia, the degree of the constriction and the number of the pathologically altered coronary arteries, the incidence of NLP, DLP and type IV HLP distinctly decreased, whereas IIa and IIB type HLP increased.
对37例慢性缺血性心脏病（IHD）患者和100名年龄在18至45岁的健康受试者进行了血清脂蛋白谱测定。在所检查的患者中，59.5%发现有高脂蛋白血症（HLP），男性为50%，女性为100%。IV型发病率最高（54.5%），其次是IIB型（36.4%）和IIa型（9.1%）。在27%未确定有HLP的患者中，发现低密度脂蛋白（LDLP）和极低密度脂蛋白（VLDLP）有不太明显的变化，被认为是血脂蛋白异常（DLP）。在所检查的患者中，86.5%证实有HLP和DLP。所有患者的高密度脂蛋白胆固醇（HDLP-Chol）血清浓度均降低（主要在DLP和IV型HLP中），而大多数情况下高密度脂蛋白甘油三酯（HDLP-Tg）水平升高。结果，脂蛋白内指数1(2)(=HDLP-Chol/HDLP-Tg)降低，在IIa型和IV型HLP中达到最低值。在所有研究指标中，唯一在所有IHD患者组（包括血脂蛋白正常（NLP）组）中有统计学意义改变（升高）的指标是脂蛋白指数II(=LDLP-Chol和VLDLP-Chol/HDLP-Chol)。随着根据心电图数据评估的病情进展、心绞痛的功能阶段、狭窄程度以及病理改变的冠状动脉数量，NLP、DLP和IV型HLP的发病率明显降低，而IIa型和IIB型HLP增加。
